Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03101293 · ClinicalTrials.gov registry record · Phase 1
A Study to Evaluate the Effect of Food on the Pharmacokinetics of TAK-831 Tablet Formulation
A Phase 1 study, sponsored by Neurocrine Biosciences.
- Completed
- Registry status
- Phase 1
- Development phase
- 15
- Enrollment target
NCT03101293 is a Phase 1 study that has completed, run by Neurocrine Biosciences. The registered enrollment target is 15 participants.
The verdict
NCT03101293, a Phase 1 study, has completed, sponsored by Neurocrine Biosciences.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 15 participants
- Enrollment target
Study Summary
The purpose of this study is to determine the pharmacokinetic (PK) of a single oral dose of TAK-831 400 milligram (mg) in the fasted state and to estimate the effect of food on the PK of a single oral dose of TAK-831 400 mg when administered as tablet formulation in healthy participants.
Interventions
- DRUG TAK-831
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2017-04-04 |
| Est. Completion | 2017-05-26 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03101293
The ClinicalTrials.gov registry entry for NCT03101293 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 15 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Neurocrine Biosciences, which has 65 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which TAK-831 is the first listed.
NCT03101293 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03101293 about?
NCT03101293 is a clinical study titled "A Study to Evaluate the Effect of Food on the Pharmacokinetics of TAK-831 Tablet Formulation". The purpose of this study is to determine the pharmacokinetic (PK) of a single oral dose of TAK-831 400 milligram (mg) in the fasted state and to estimate the effect of food on the PK of a single oral dose of TAK-831 400 mg when administered as tablet formulation in healthy participants.
What is the current status of trial NCT03101293?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 15 participants. The study started on 2017-04-04. Estimated completion is 2017-05-26.
What interventions are being tested in trial NCT03101293?
The interventions under investigation include: TAK-831 (DRUG).
Who is sponsoring clinical trial NCT03101293?
This trial is sponsored by Neurocrine Biosciences, which has 65 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.